BP
RCKT icon

Ballentine Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Ballentine Partners’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$241K Sell
70,405
-18,596
-21% -$61.8K ﹤0.01% 917
2026
Q1 		$319K Sell
89,001
-8,624
-9% -$34.3K ﹤0.01% 708
2025
Q4 		$343K Buy
97,625
+9,055
+10% +$31K ﹤0.01% 661
2025
Q3 		$289K Buy
+88,570
New +$279K ﹤0.01% 730

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ballentine Partners's RCKT Position: Q2 2026 in Review

Ballentine Partners reduced its Rocket Pharmaceuticals (RCKT) stake by 21% in Q2 2026, selling an estimated $61.8K and leaving 70,405 shares worth $241K. The position accounts for ﹤0.01% of the portfolio, ranked #917.

Ballentine Partners first reported a position in RCKT in Q3 2025 and has held it in 4 quarters since. The position peaked at $343K in Q4 2025. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Ballentine Partners held 70,405 shares of Rocket Pharmaceuticals worth $241K as of Q2 2026.
  • Ballentine Partners sold 18,596 Rocket Pharmaceuticals shares in Q2 2026, an estimated $61.8K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #917 holding.
  • Ballentine Partners first reported a position in Rocket Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Ballentine Partners's Rocket Pharmaceuticals position peaked at $343K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.